Show results for
Refine by
Cancer Drive Gene Mutations Detection Suppliers Serving Lithuania
32 companies found
based inHuntsville, ALABAMA (USA)
Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to ...
based inKowloon Bay, HONG KONG
Hybribio, a leader in molecular diagnostic products in China, is engaged in the nucleic acid diagnostic field. It provides a full operation chain from research and development to production and sales. The company's capabilities are enriched by an ...
The Stool DNA Methylation Real-time PCR Kit serves as a diagnostic tool for individuals at high risk of colorectal cancer, facilitating in vitro qualitative detection of methylated SDC2 and TFPI2 genes within intestinal exfoliated cells. Designed ...
based inNatick, MASSACHUSETTS (USA)
DYSIS Medical is a medical device company that designs, develops, manufactures and markets imaging systems focusing on the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. DYSIS Medical has developed a proprietary technology ...
based inSeoul, SOUTH KOREA
We detect and analyze genomic profile of tumor DNA with a single draw of blood. With this comprehensive profile, we provide personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Ultimately, we ...
AlphaLiquid® Screening is a blood-based test for early detection of multiple cancers. With 10mL of blood, the test analyzes genetic and epigenetic features in cfDNA to screen for signals of cancer as well as predict the tissue of origin. ...
based inSan Diego, CALIFORNIA (USA)
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses ...
Liquid biopsies are a new powerful tool in cancer diagnostics that is transforming patient healthcare. Body fluids such as blood or urine are obtained from the patient and analyzed for the presence of circulating tumor DNA which is shed from the ...
based inLund, SWEDEN
Our mission is to make it easier to analyze the huge amounts of complex data that are generated by innovations in the fields of genetics and proteomics. We do this by providing powerful visualization-based bioinformatics data analysis tools for ...
based inIsfiya, ISRAEL
At Check-Cap our experienced and motivated team is committed to increasing screening adherence and helping to reduce the global incidence of colorectal cancer (CRC) through cancer prevention. Our patented technology C-Scan is the first and only ...
based inAmsterdam, NETHERLANDS
Self-screen has a long history and track record in translational HPV related science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of HPV related cancer screening into routine practice. Our ...
The QIAsure Methylation Test is intended to be used as a triage test for women with a positive HPV DNA test or for women with ASC-US cytology to identify those women who need to be referred for colposcopy. The QIAsure Methylation Test is a multiplex ...
based inWaterside, UNITED KINGDOM
Lightpoint Medical is a technology leader in targeted cancer surgery. We are developing miniaturized imaging and sensing tools for more precise intra-operative cancer detection. Our mission is to improve the lives of people with cancer by ...
Using next-generation miniaturized sensor technology, the SENSEI probe measures just over 40mm in length, enabling unprecedented intracavity maneuverability and anatomic access for surgical ...
based inNottingham, UNITED KINGDOM
Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based ...
EarlyCDT is a simple blood test that detects the elevated presence of autoantibodies generated by the body's immune system as a natural defence against cancer cells. EarlyCDT Lung is the world’s most thoroughly validated blood test for the ...
based inGuangzhou, CHINA
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy ...
Cancer is a complicated disease caused by genetic variation. The genetic variation may deprive cells of the normal control function, leading to immortalization and cancer. And targeted drugs work well in cancer therapy, which can kill cancer cells ...
based inSykesville, MARYLAND (USA)
OTraces, Inc. has built, and extensively filed patents protection on, an early tumor detection and cancer screening software technology. Technology uses well-known math- and physics-based A-I methods including those used in advanced satellite ...
BC Sera Dx Immunoassay test panel for detection of the presence of breast cancer in women. In the development pipeline are an Ovarian, OV Sera Dx, and Lung, LG Sera Dx, cancer detection test ...
based inSan Juan Capistrano, CALIFORNIA (USA)
In late 1999, out of an urge to innovate and excel, John Bottjer, Nizar Mullani, and Thorsten Trotzenberg founded 3Gen as a cutting-edge product design and development company situated in beautiful Orange County, California. At the 2001 meeting of ...
based inLondon, UNITED KINGDOM
At Kheiron, we believe that by combining human intelligence with the power of AI, we can help transform cancer diagnostics. Detecting cancer and tracking it accurately is challenging and time-consuming for even the most experienced radiologists. ...
Mia® is our breakthrough AI platform for breast screening. A suite of solutions, Mia empowers radiologists and screening services to deliver confident, accurate and timely results to every woman, everywhere. Discover how Mia delivers ...
based inLondon, UNITED KINGDOM
Getting ahead of cancer is crucial no matter where people are in their cancer journey. From earlier cancer detection to treatment guidance and monitoring, we are helping people get the answers they need to make more informed decisions across the ...
based inSeville, SPAIN
We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable. We are developing Signal-X™, a multi-cancer platform able to detect various types of high-burden ...
We are developing Signal-X, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. ...
based inMilan, ITALY
Tethis S.p.A is based in Milan, Italy, and is developing a novel workflow to bring liquid biopsy in the clinical practice for the precise management of cancer. Tethis’ technology points to standardization of the blood sample preparation to provide ...
based inMiserey, FRANCE
Innovative Solutions for Cancer Diagnostics. OncoDiag is a French biotechnology company based in Normandy at one hour from Paris and Rouen cities. The company is focused on developing of non-invasive diagnostic tests for early detection of cancers. ...
based inOrlando, FLORIDA (USA)
Imaging Diagnostic Systems, Inc. (IDSI) is a medical device company headquartered in Florida, specializing in the research, development, and marketing of innovative cancer detection systems. Their flagship product, the CTLM system (Computed ...
Computed Tomography Laser Mammography (CTLM) is an innovative imaging method focused on visualizing blood distribution within the breast, helpful for identifying breast abnormalities. This technology offers potential advantages in detecting ...
based inNew York, NEW YORK (USA)
Acuamark Diagnostics develops technology which allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team of scientific and business ...
The vast majority of cancer cases are detected at stage III or beyond, resulting in poor cancer survival of ~50% in the aggregate. Cancer cases are forecasted to reach 25M per year over the next two decades, causing deaths to rise to 13M per ...
